A PYMNTS Company

US: FTC seeks more info on Pfizer-Hospira deal

By  |  May 14, 2015

Pfizer said Thursday that the US Federal Trade Commission is seeking more information about its proposed $15.2 billion acquisition of Hospira before it decides on whether the deal violates antitrust laws.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Pfizer said the FTC’s so-called “second request” was expected and that it has worked “cooperatively and expeditiously” to help the agency complete its review.

    Pfizer, seeking to tap into the biosimilars market to provide cheaper alternatives to biologic drugs, announced the purchase of Hospira in February. The acquisition was expected to close in the second half of this year, and Pfizer said the FTC move didn’t alter its timeline.

     

    Full content: Business Wire

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.